Navigation Links
FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
Date:11/24/2009

WOODCLIFF LAKE, N.J. and NEW YORK, Nov. 24 /PRNewswire/ -- Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl extended release) tablets for the treatment of moderate to severe Alzheimer's disease (AD). This new higher dose formulation contains 23 mg of donepezil HCl in an extended release, matrix-type tablet with a delivery system that allows for gradual release of the drug. The NDA is based on a head-to-head clinical study comparing the 23 mg Aricept extended release tablet to the currently marketed once daily 10 mg Aricept® (donepezil HCl) immediate release tablet. More than 1400 patients with moderate to severe Alzheimer's disease were enrolled in this global study.

Acceptance of the NDA indicates that the FDA has found the company's submission to be sufficiently complete to review. Eisai and Pfizer believe this new formulation will potentially provide physicians, patients and their families with another option for the management of Alzheimer's disease.

About Aricept® (donepezil HCl) tablet

Aricept is the first and only prescription medication approved by the FDA for the treatment of all stages of AD -- mild, moderate and severe dementia of the Alzheimer's type. This indication is supported by evidence-based medicine, with numerous well-controlled clinical studies of AD in all stages and multiple settings among thousands of patients, demonstrating that Aricept improves cognition and slows the decline of overall function. Aricept is currently available in 5 mg and 10 mg immediate release tablets, dosed once daily. It is co-promoted in the United States by Eisai Inc. and Pfizer Inc.

Aricept is well tolerated but may not be for everyone. People at risk for stomach ulcers or who take certain other medicines should tell t
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
2. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
5. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
6. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
7. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
11. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... March 23, 2011 Available at ... this patent portfolio discloses methods and techniques related to ...   http://photos.prnewswire.com/prnh/20100614/CG20517LOGO ) Background ... has inherent problems. Orally administered drugs (e.g., tablets or ...
... March 23, 2011 In a letter ... Federal Trade Commission (FTC) warns that a bill shifting ... Mississippi Insurance Commissioner to the Board of Pharmacy "may ... states that the Mississippi legislature should "seriously consider whether ...
Cached Medicine Technology:ICAP Ocean Tomo Announces Auction of Patch Based Drug Delivery and Monitoring Techniques from Entrega Laboratories, LLC 2ICAP Ocean Tomo Announces Auction of Patch Based Drug Delivery and Monitoring Techniques from Entrega Laboratories, LLC 3Federal Trade Commission: Mississippi SB 2445 'Likely Will Increase Drug Costs, Reduce Competition' 2
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
(Date:7/9/2014)... found that fecal transplantation is effective and safe for ... is the result of a study led by Colleen ... Gastrointestinal Medicine at The Women,s Medicine Collaborative. The study ... of print in the American Journal of Gastroenterology ... diff , has increased to epidemic proportions over the ...
(Date:7/9/2014)... There has been a sharp increase in the number ... MyChart, the online, interactive service that allows patients to ... providers, schedule appointments, and renew prescriptions. , Over a ... MyChart each year increased five-fold, while the number ... according to a study by Dr. David Gerber ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... , , , , , , ... , , , , , ... a binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the ... , , , , ... , , , , , ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... 2008 -- In the December issue of ... Nickel and associates report on the evidence of ... tract symptoms (LUTS) in men enrolled in the ... of prostate Cancer Events) trial is a 4-year, ...
... Northridge Hospital Medical,Center (Northridge) credits TeleHealth Services, ... the organization,s recent awards and top,accreditation, all ... comfort as its medical experts provide superior ... acute care facility located in Northridge, CA,Northridge ...
... Indication for Bothersome Vaginal Symptom Associated,With Menopause, ... Cream 0.5 g has been approved by the ... indication and a new less,frequent twice-weekly dosing regimen ... intercourse) announced Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: ...
... traditional chemotherapy agents with targeted therapies called monoclonal ... in patients with advanced non-small cell lung cancer ... Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ... The combination of bevacizumab and chemotherapy has been ...
... A new research study underway at Cardiff University ... treatment failure among patients with end-stage kidney disease. ... Inflammation Interdisciplinary Research Group at the School of ... the ,Renal Discoveries - The Baxter Extramural Grant, ...
... one of those shoppers who,wake up at 4am on Black ... "It is important not to disturb your circadian rhythm ... SSA. "The body,operates better on a good night,s sleep which ... of dawn the day after Thanksgiving.", SSA retailers nationwide ...
Cached Medicine News:Health News:Relationship between prostate information and lower urinary-tract symptoms evident 2Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 2Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 2Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 4Health News:Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients 2Health News:Cardiff scientists study acute infection in end-stage kidney disease patients 2Health News:Don't Disturb Your Circadian Rhythm This Black Friday 'Sleep In, Nap Later,' says Specialty Sleep Association 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: